EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Ethical, legal, and social implications of AI-enabled digital therapeutics: A comparative analysis of risk-based regulatory frameworks in the European Union and Japan

Yasue Fukuda iD, Koji Fukuda

DIGITAL HEALTH · 2026-02 · 12

DOI: 10.1177/20552076261444907 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift DIGITAL HEALTH, online erschienen am 19.04.2026. Verfasst von Yasue Fukuda und 1 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, Japan. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Digital therapeutics (DTx) and other forms of therapeutic artificial intelligence (AI) are becoming increasingly embedded in healthcare systems and everyday health practices. Unlike earlier forms of medical AI, which mainly support diagnostic decision-making, therapeutic AI systems interact continuously with patients and may influence health-related behaviour over time. These characteristics raise ethical, legal, and social implications (ELSI) that extend beyond conventional concerns about safety, efficacy, and algorithmic performance. This article examines how such concerns are translated into institutional practice by reconceptualizing ELSI as governance infrastructure. Drawing on a narrative review combined with comparative institutional analysis, it analyses regulatory frameworks, policy documents, and governance arrangements in two advanced digital health jurisdictions: the European Union and Japan. The analysis identifies two distinct governance models. The European Union has developed a layered regulatory framework in which the Artificial Intelligence Act operates alongside the Medical Device Regulation, the General Data Protection Regulation, and emerging health-data governance initiatives. Japan, by contrast, governs therapeutic AI primarily through sectoral legislation centred on the Pharmaceuticals and Medical Devices Act, complemented by administrative guidance and professional mediation. These approaches illustrate different ways of embedding ELSI within digital health governance. The EU model emphasizes codified ex ante obligations and legally binding compliance mechanisms, whereas the Japanese model places greater weight on adaptive oversight and post-market learning. Effective governance of therapeutic AI, the article argues, requires institutional infrastructures capable of addressing behavioural influence, lifecycle change, and accountability across AI-enabled therapeutic systems.

Schlagwörter

Stichwörter der Autor:innen

ELSIEU AI actJapandigital therapeutics (DTx)risk-based regulationtherapeutic AI

Autor:innen und Institutionen

  • Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie, Japan.
  • Faculty of Political Science and Economics, Waseda University, Shinjuku-ku, Japan.

ORCID-Profile: Yasue Fukuda

Zitieren

APA

Fukuda, Y., & Fukuda, K. (2026). Ethical, legal, and social implications of AI-enabled digital therapeutics: A comparative analysis of risk-based regulatory frameworks in the European Union and Japan. DIGITAL HEALTH, 12. https://doi.org/10.1177/20552076261444907

Vancouver

Fukuda Y, Fukuda K. Ethical, legal, and social implications of AI-enabled digital therapeutics: A comparative analysis of risk-based regulatory frameworks in the European Union and Japan. DIGITAL HEALTH. 2026;12. doi:10.1177/20552076261444907

BibTeX
@article{Fukuda2026,
  author = {Fukuda, Yasue and Fukuda, Koji},
  title = {Ethical, legal, and social implications of AI-enabled digital therapeutics: A comparative analysis of risk-based regulatory frameworks in the European Union and Japan},
  journal = {DIGITAL HEALTH},
  year = {2026},
  volume = {12},
  doi = {10.1177/20552076261444907}
}
Kostenlos starten →